Molsidominum Pph (Molsidomine)

Molsidomine, the active ingredient in Molsidominum Pph, is a nitric oxide donor presented as an oral tablet for oral use. It is employed in the management of stable angina pectoris and chronic stable angina, helping to reduce myocardial oxygen demand in adult patients.

GNH USA supplies Molsidominum Pph as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation for importers. Its global distribution network ensures timely delivery to authorized healthcare facilities.

Molsidomine is a nitric oxide donor used in the treatment of angina‑related conditions. - Stable angina pectoris: reduces frequency of chest pain episodes by improving coronary blood flow. - Chronic stable angina: helps maintain exercise tolerance and decreases myocardial oxygen demand. - Effort‑induced angina: alleviates symptoms during physical activity.

Molsidomine may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dosing. - Dizziness: transient sensation of light‑headedness, especially when standing quickly. - Flushing: warm sensation and reddening of the skin, often on the face or neck. - Nausea: mild gastrointestinal upset that may occur after the dose. - Tachycardia: increase in heart rate, usually transient.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Syncope: sudden loss of consciousness related to blood pressure fall. - Allergic reactions: rash, itching, swelling, or anaphylaxis in rare cases. - Myocardial infarction: rare occurrence of heart attack possibly linked to severe hypotension. - Hemolysis: rare destruction of red blood cells reported in isolated cases.

When prescribing Molsidomine, clinicians should consider several precautionary measures to ensure safe use. - Cardiovascular assessment: evaluate blood pressure and cardiac status before initiating therapy. - Concomitant nitrates: avoid combined use due to risk of additive hypotensive effects. - Renal impairment: adjust therapy cautiously in patients with severe renal dysfunction. - Elderly patients: monitor closely for hypotension and dizziness. - Drug interactions: review patient medication list for phosphodiesterase inhibitors. - Pregnancy: use only if potential benefit justifies potential risk to fetus. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Molsidomine can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Nitrates: concurrent administration can lead to profound hypotension, dizziness, and syncope, therefore it should be avoided. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): combined use may cause severe blood pressure reductions and should be avoided. - Antihypertensives: additive blood‑pressure‑lowering effects may increase risk of hypotension; dose adjustments may be required.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the compensatory increase in heart rate, potentially reducing anti‑anginal efficacy; monitor heart rate. - Diuretics: may potentiate the hypotensive effect of Molsidomine; observe blood pressure closely. - Calcium channel blockers: possible additive vasodilation may lead to excessive blood pressure fall; consider monitoring.